Introduction
The activating transcription factor-2 (ATF-2) is a member of the ATF family, whose members bear a b-Zip type DNA-binding domain (Maekawa et al., 1989) . ATF-2 can form homodimers or heterodimers with c-Jun, and binds to the cyclic AMP response element (CRE). Stress-activated protein kinases (SAPKs) including p38 phosphorylate ATF-2 and enhance its trans-activating capacity (Gupta et al., 1995) . The SAPKs themselves are activated by various extracellular stresses including UV light (Chang and Karin, 2001) . While the SAPKs-ATF-2 pathway is believed to play a role in stress-induced apoptosis, its precise role remains elusive.
Null Atf-2 mutant mice die shortly after birth and display symptoms of severe respiratory distress including lungs filled with meconium (Maekawa et al., 1999) . By using Atf-2 À/À mouse embryonic fibroblasts (MEFs), we recently showed that ATF-2 plays a role in hypoxiainduced apoptosis (Maekawa et al., 2007) . ATF-2 is involved in the apoptosis at the saturation cell density, and the loss of one copy of Atf-2 facilitates the activated ras-mediated transformation of cultured cells. Furthermore, Atf-2 þ /À mice are highly prone to mammary tumors.
In response to hypoxia, ATF-2 activates multiple target genes, including Gadd45a, which is a regulator of apoptosis (Takekawa and Saito, 1998) . Gadd45a is a target gene of BRCA1 (Harkin et al., 1999) and p53 (Kastan et al., 1992) . Gadd45a also contributes to p38 activation (Mita et al., 2002) , suggesting the positive feedback loop involving p38, ATF-2 and Gadd45a.
Gadd45a
À/À mice show defects in genomic stability, nucleotide excision repair and cell proliferation (Hollander et al., 1999) .
In the absence of hypoxia, ATF-2 also activates some genes including Maspin, which encodes a member of the serine protease inhibitor family (Maekawa et al., 2007) . Maspin was identified as a tumor suppressor in human breast cancers (Zou et al., 1994) . Maspin inhibits angiogenesis, tumor cell growth and invasion (Zhang et al., 2000; Cher et al., 2003) , while it enhances cellular sensitivity to apoptotic stimuli (Liu et al., 2004) . The expression of Maspin is regulated by p53 (Zou et al., 2000) . In the mammary tumors arisen in Atf-2 þ /À mice, downregulation of both Gadd45a and Maspin was observed (Maekawa et al., 2007) . However, it remains unknown how ATF-2 regulates the transcription of those genes.
Here, we have demonstrated that ATF-2 directly regulates the transcription of GADD45a and Maspin in a p53-independent fashion. Consistent with this is that the loss of one copy of p53 stimulates mammary tumor formation in Atf-2 þ /À mice.
Results

ATF-2 is required for the BRCA1-dependent transcription of GADD45a
Gadd45a transcription is independently activated by p53 and BRCA1. p53 activates the Gadd45a transcription via the p53-binding site in the third intron. ATF-2 activates Gadd45a transcription independently from p53 in response to hypoxic stress or anisomycin (AM) treatment (Maekawa et al., 2007) . Recombinant ATF-2 did not bind to the GADD45a promoter (data not shown). Co-expression of BRCA1 with the GADD45a promoter-luciferase reporter in p53 À/À cells enhanced luciferase expression 3.8-fold, but this induction was not observed in Atf-2
À/À cells ( Figure 1a ). This suggests that ATF-2 is required for the BRCA1-mediated activation of the GADD45 promoter. Furthermore, HA-BRCA1 co-precipitated with FLAG-ATF-2 in immunoprecipitation experiments (Figure 1b) .
BRCA1 enhanced the luciferase expression from the GADD45a promoter containing the -107/ þ 144 region, but not from the promoter containing the -62/ þ 144 region ( Figure 1c) . Thus, the region between -107 and -62 is critical for the BRCA1-dependent activation. This is consistent with the previous report that the Oct-1 sites and the CAAT motif, which were located in the region between -100 and -62, are responsible for BRCA1-induced activation (Fan et al., 2002) and that the induction of GADD45a transcription by UV is mediated by the Oct-1-binding sites (Takahashi et al., 2001) .
The mutant promoter constructs were co-transfected with a BRCA1 expression vector into MEFs, and the amount of luciferase mRNA was analysed (Figure 1d ). We used RNase protection assays rather than the luciferase assays because we used AM to activate ATF-2; AM is a translation inhibitor. BRCA1 and AM treatment increased the luciferase mRNA levels 8-and 7.8-fold, respectively, in p53 À/À cells but had no effect in Atf-2
À/À cells. Disruption of either the three Oct-1 binding sites alone or the Oct-1-binding sites plus the CAAT motif almost completely abrogated the BRCA1-and AM-induced activation in p53 À/À cells. Thus, the Oct-1 sites and the CAAT motif in the GADD45a promoter are required for the ATF-2-and BRCA1-dependent induction in response to stress.
ATF-2 binds to BRCA1, Oct-1 and NF-I To investigate the interaction among ATF-2, BRCA1, Oct-1 and NF-I, which bind to the CAAT motif (Osada et al., 1996) , on the GADD45a promoter, we performed the DNA precipitation experiments. Lysates prepared from MCF-7 cells were mixed with the 32 P-labeled GADD45a promoter fragment and precipitated with anti-ATF-2, anti-BRCA1 or anti-Oct-1 antibodies. The wild-type GADD45a promoter fragment was precipitated with all three antibodies, unlike a mutant fragment in which the Oct-1 sites were mutated ( Figure 1e ). We also performed the co-immunoprecipitation experiments. The anti-ATF-2 and anti-BRCA1 antibodies co-precipitated Oct-1, while the anti-NF-I antibodies co-precipitated ATF-2 (Figure 1f) .
In vitro translated ATF-2 bound to three glutathione-S-transferase (GST) fusion proteins containing either the full-length Oct-1 protein or its N-or C-terminal half (Figure 2a) . In vitro translated NF-I also bound to the three GST-Oct-1 fusions (Figure 2a) . Thus, ATF-2 and NF-I bind to both the N-and C-terminal halves of Oct-1. In vitro translated ATF-2 also bound to the GST-NF-I fusion (Figure 2b ). In vitro translated ATF-2, Oct-1 and NF-I all bound to the GST-BRCA1 fusion containing amino acids 341-749 of BRCA1 (Figure 2c ). The results using various mutants of ATF-2 revealed that the b-Zip region is critical for binding to BRCA1 (Figure 2d ), indicating that this interaction does not require the phosphorylation of ATF-2 at Thr-69 and Thr-71. This suggests that the phosphorylation of ATF-2 has another role, such as an abrogation of Figure 1 ATF-2 is required for BRCA1-dependent activation of the GADD45a promoter. (a) BRCA1-dependent activation of the GADD45a promoter is impaired in Atf-2 À/À p53 À/À cells. The GADD45a promoter-luciferase reporter was co-transfected into p53 À/À or Atf-2 À/À p53 À/À cells with a BRCA1 expression vector, and luciferase activity was measured. The averages and SEMs of three experiments are shown. (b) BRCA1 co-immunoprecipitates ATF-2. The FLAG-ATF-2 and HA-BRCA1 expression plasmids were cotransfected into 293 cells. Lysates were prepared and immunoprecipitated with the indicated antibodies. The immunocomplexes were analysed by western blotting using the indicated antibodies (upper two panels). Western blots of the cell lysates are also shown (lower two panels). (c) The critical region of the GADD45a promoter for BRCA1-dependent activation. The GADD45a promoter-luciferase reporter, which contained the -107/ þ 144 region or the -62/ þ 144 region, was co-transfected into p53
À/À cells with a BRCA1 expression vector, and the amount of luciferase mRNA was measured using real-time RT-PCR. The averages and SEMs of three experiments are shown. (d) The Oct-1 sites and CAAT motif are required for the BRCA1-and ATF-2-dependent GADD45a promoter activation. The GADD45a promoter-luciferase reporters used are shown (top). (Left) p53 À/À or Atf-2 À/À p53 À/À cells were co-transfected with the indicated GADD45a promoter-luciferase reporters with the BRCA1 expression plasmid and the internal control Renilla luciferase plasmid containing the SV40 promoter, and the amount of luciferase mRNA was measured by using a RNase protection assay. (Right) p53 À/À or Atf-2 À/À p53 À/À cells were co-transfected with the indicated GADD45a promoter-luciferase reporters and the internal control plasmid containing the TK promoter and treated with anisomycin (AM) for 4 or 12 h before being harvested. The luciferase mRNA levels were measured by the RNase protection assay. The relative amount of firefly luciferase mRNA was normalized to the internal control luciferase mRNA levels. (e) ATF-2 and BRCA1 are recruited to the GADD45a promoter via its Oct-1 sites. The 32 P-labeled DNA fragment (nucleotides À112 to þ 287) containing the wild-type GADD45a promoter or its mutant, in which two Oct-1 sites are mutated, was mixed with the nuclear extract of MCF-7 cells. The mixtures were then immunoprecipitated with the indicated antibodies and the presence of the 32 P-DNA fragment in the immunocomplex was analysed by agarose gel electrophoresis. (f) Coimmunoprecipitation of endogenous ATF-2, BRCA1, Oct-1 and NF-I. The lysates from MCF7 cells were immuno-precipitated with the indicated antibodies. The immunocomplexes were then analysed by western blotting using the indicated antibodies.
ATF-2 regulates Maspin and Gadd45a transcription T Maekawa et al the ATF-2-corepressors interaction in the absence of stress. Thus, in response to stresses, ATF-2 is recruited by Oct-1, NF-I and BRCA1 to the GADD45a promoter ( Figure 2e ).
Activation of Maspin transcription by ATF-2
The Maspin mRNA levels in Atf-2 À/À and p53 À/À MEFs were lower than those in wild-type cells (Figure 3a) . The Maspin mRNA levels in Atf-2
À/À cells were ATF-2 regulates Maspin and Gadd45a transcription T Maekawa et al À/À or p53 À/À Atf-2 À/À MEFs were transfected with the indicated Maspin promoter-luciferase constructs, the transfectants were pooled and their luciferase activities were measured. The CRE-like sequence is indicated by bold letter. (e) Binding of ATF-2 to the Maspin promoter. (Left) The glutathione-S-transferase (GST)-ATF-2 protein was analysed by SDS-PAGE followed by Coomassie staining. (Right) Gel mobility shift assays were performed using the GST-ATF-2 protein and the probe containing the CRE-like element from the Maspin promoter. In some lanes, the competitor oligonucleotide containing the wild-type or mutated CRE-like site, or the anti-ATF-2 antibody, was added.
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assays. The luciferase expression in p53
À/À cells was threefold higher than that in Atf-2 À/À p53 À/À cells ( Figure 3c) .
The p53 À/À and Atf-2 À/À p53 À/À transfectants containing various mutant Maspin promoter-luciferase constructs were isolated, pooled and used for luciferase assays (Figure 3d) . The À764/ þ 91 promoter construct, which contains the region between À764 and þ 91 ( þ 1 is the reported RNA start site), had a 3.4-fold higher luciferase expression in Atf-2 þ / þ cells compared to that in Atf-2 À/À cells. An enough degree of ATF-2-associated enhancement (8.2-fold) was observed with the À116/ þ 91 promoter construct, although the À764/À116 region exerted repressive effects on the ATF-2 responsiveness. In the previous report using the mammary epithelial cells (Zhang et al., 1997) , this region had no repressive effect, suggesting that the difference may be due to the cells used. In contrast, ATF-2 did not Maekawa et al., 2007) mice. The P-value obtained by the Mantel-Cox log-rank test:
0127. Mammary tumors were found in 5 of the 33 Atf-2 þ /À p53 þ /À mice along with other types of tumors. These tumors are described in Table 1 
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significantly enhance the luciferase expression from the À116/ þ 60 construct. The region between þ 61 and þ 91 contains a CRE-like sequence (TGAGCCA). When this site was mutated (À116/ þ 91-mut), the ATF-2-induced trans-activation was abrogated. In gel-mobility shift assays, a recombinant ATF-2 protein bound to the DNA probe containing this CRE-like element (Figure 3e ). DNA containing the wild-type sequence, but not DNA containing the mutated sequence (À116/ þ 91-mut), competed for binding. The anti-ATF2 antibody super-shifted the retarded band. Thus, ATF-2 directly binds to the CRE-like element in the Maspin promoter and activates transcription.
Loss of one copy of p53 shorten the period required for mammary tumor development in Atf-2 þ /À mice ATF-2 and p53 independently activate the transcription of GADD45a and Maspin, raising the possibility that the mammary tumor formation in Atf-2 þ /À mice could be enhanced by the loss of one copy of p53. To examine this, we generated double-heterozygotes of Atf-2 and p53 (Atf-2 (Figure 4a ). Various types of mammary tumors (invasive ductal carcinoma with solid-tubular and papillary invasion, carcinoid with Grimelius staining positive cells and sarcomatoid carcinoma) developed in 5 of 33 Atf-2
þ /À mice at the age of 27-60 weeks (Figures 4b-d and Table 1 ). Of the five mammary tumors, two developed in male mice. No mammary tumors were observed in p53 þ /À mice during the period of 83 weeks, as reported previously (Donehower et al., 1992) . Since mammary tumors only developed in Atf-2 þ /À mice at the age of 57-103 weeks, and occurred only in female mice (Maekawa et al., 2007) , these results indicate that the loss of one copy of p53 shortened the period required for mammary tumor development in female mice and predisposed male mice to mammary tumors. Furthermore, the loss of one copy of p53 induced great diversity in types of mammary tumors compared to those found in Atf-2 þ /À mice. Gadd45a and Maspin expression was lost or reduced in all the mammary tumors that developed in Atf-2 þ /À mice, while nearly all also showed reduced or absent Atf-2 expression (Maekawa et al., 2007) . Similarly, of the three mammary tumors from Atf-2
þ /À mice, Atf-2 mRNA expression was lost in one and reduced in two ( Figure 4e and Table 1 ). Gadd45a and Maspin expression was also lost in all three of these mammary tumors. p53 expression was not lost in any of the tumors. Thus, like the mammary tumors from Atf-2 þ /À mice, the mammary tumors from Atf-2
þ /À mice showed a severe reduction in Atf-2, Gadd45a and Maspin expression.
Loss of one copy of p53 also induces other types of tumors in Atf-2 þ /À mice In addition to mammary tumors, Atf-2
þ /À mice also developed many other types of tumors (invasive ductal carcinoma with solid-tubular invasion, carcinoid, Carcinoid, carcinoid with Grimelius staining-positive cells (data not shown); Idc. papillary, invasive ductal carcinoma with papillary invasion; Idc. solid-tubular, invasive ductal carcinoma with solid-tubular invasion; Mali. fib. histio., malignant fibrous histiocytoma; ND, not determined due to degradation of tissues and mRNA; Red, the expression level was reduced to 10-60% of that in wild-type mammary gland; Sarcomatoid, sarcomatoid carcinoma; +, the expression level was almost the same as that in wild-type mammary gland; À, almost no expression.
ATF-2 regulates Maspin and Gadd45a transcription T Maekawa et al sarcomatoid carcinoma and malignant fibrous histiocytoma) in other organs at the age 21-73 weeks (Figures 5a-c and Table 1 ). Eight of the 20 p53 þ /À mice developed tumors at the age 41-80 weeks, about 50% of which were lymphomas, as has been previously described (Donehower et al., 1992) . Carcinoid and sarcomatoid carcinoma were not observed in p53 þ /À mice. Thus, the loss of one copy of the p53 gene accelerated the development of various tumors in Atf-2 þ /À mice. Atf-2 mRNA expression was reduced in all 14 nonmammary tumors found in Atf-2 (Figure 5d and Table 1 ), while Gadd45a expression was lost in six, reduced in seven and not affected in one. Furthermore, Maspin expression was lost in 11 tumors and reduced in 3. p53 expression was not lost in any of the tumors. Thus, reductions in Atf-2, Gadd45a and Maspin expression were also observed in tumors from Atf-2
þ /À mice other than the mammary tumors.
Discussion
ATF-2 and p53 independently regulate the transcription of Maspin and GADD45a. Thus, a disruption of both the ATF-2 and p53 pathways may completely impair Maspin and GADD45a expression. The loss of one copy of p53 in Atf-2 þ /À mice led to an earlier onset of mammary tumor development, which supports the notion that ATF-2 and p53 independently regulate Maspin and Gadd45a expression. Although both ATF-2 and p53 are activated by stress, different stressors may preferentially activate one or the other. This idea suggests that like p53, ATF-2 is involved in the development of various types of cancers.
A significant body of evidence implicates BRCA1 in transcriptional regulation and interacts with various transcriptional regulators (Venkitaraman, 2002) . Our results suggest that ATF-2 simultaneously binds to Oct-1, NF-I and BRCA1 on the GADD45a promoter. After ionizing radiation, BRCA1 is activated by releasing ATM-phosphorylated CtIP and then induces GADD45a transcription (Li et al., 2000) . Therefore, activated BRCA1 and ATF-2 that have been phosphorylated by SAPKs may be recruited to the GADD45a promoter. The transcriptional activation domain of ATF-2 may synergistically activate the GADD45a gene promoter together with the activation domains of Oct-1, NF-I and BRCA1. Thus, BRCA1 may act as a scaffold protein that is needed to maintain the correct architecture of the transcriptional machinery on the target promoter.
We found that 15 of 24 Atf-2 þ /À mice (62.5%) developed mammary tumors and had T 50 of tumor-free survival of about 90 weeks (Maekawa et al., 2007) . On the other hand, only 3 of 10 mammary epitheliumspecific Brca1 knockout mice were shown to develop mammary tumors in at the age of 10-13 months (Xu al., 1999) . The loss of one copy of p53 accelerates the formation of mammary tumors in both Atf-2 þ /À mice and the mammary epithelium-specific Brca1 knockout mice (Xu et al., 1999) . Mammary tumors developed in 5 of 33 Atf-2
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þ /À mice at the age of 27-60 weeks, 2 of which occurred in male animals. However, of the 11 mammary epithelium-specific Brca1 knockout mice lacking a copy of p53 that were examined, 8 developed mammary tumors at the age of 24-32 weeks, all of which were female (Xu et al., 1999) . The enhancement of tumor susceptibility in Atf-2 þ /À and mammary epithelium-specific Brca1 knockout mice that is induced by the loss of one p53 copy could be related to Gadd45a. Since stress-induced Gadd45a expression appears to be controlled independently by p53 and the ATF-2-BRCA1 complex, a decrease in both p53 and ATF-2-BRCA1 may additionally reduce the Gadd45a levels. Thus, Gadd45a may be one of the key regulators in the mammary tumor development.
Materials and methods
Promoter analysis
MEFs were prepared from the embryos as described previously (Maekawa et al., 2007) . To determine the transcription from the Gadd45a gene promoter, mixtures containing pGADD45a-Luc that harbor the GADD45a promoter and pRL-SV40 or pRL-TK as an internal control were transfected into MEFs. Twenty-four hours after the transfection, the cells were harvested and their poly(A) þ RNAs were isolated. Ten micrograms of poly(A) þ RNA was hybridized with the 32 P-labeled RNA probe, and after digestion with a mixture of RNaseA and RNaseT1, the protected bands were separated on 5% polyacrylamide-8 M urea gels. To analyse the Maspin promoter activity, the reporter plasmid containing the Maspin promoter region, pSV40-puro and 1 mg of the internal control plasmid pRL-SV40 was co-transfected into MEFs. More than 300 puromycin-resistant colonies were then pooled and used for luciferase assays.
Protein-protein interaction
In co-immunoprecipitation assays of endogenous proteins, MCF7 cells were lysed by mild sonication in NET-NB buffer and immunoprecipitation was performed using anti-ATF-2, anti-BRCA1 or anti-Oct-1 antibodies. Immunocomplexes were resolved on 10% sodium dodecyl sulfate-polyacrylamide gels, and analysed by western blotting with anti-Oct-1 or anti-NF-I antibodies. To detect the interaction with NF-I, LSLD buffer was used. The GST pull-down assays were performed using various mutants of GST-BRCA1, GST-Oct-1 or GST-NF-I and in vitro translated ATF-2, Oct-1 or NF-I.
Tumor analysis
All mice analysed had a 75% C57BL/6J and 25% CBA genetic background. Histological analysis of tumors was performed as described previously (Maekawa et al., 2007) .
Other details of the methods used herein are described in the Supplementary Information.
